Takahito Hara

Fujisawa, 2518555, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models.

Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models.

Journal: BMC cancer

Published: July 15, 2025

Pharmacological properties and clinical outcomes of the anti-cancer drug, cabozantinib (CABOMETYX®)

Pharmacological properties and clinical outcomes of the anti-cancer drug, cabozantinib (CABOMETYX®)

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: September 02, 2021

Corrigendum to "Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor" [Biochem. Biophys. Rep. 21 (2020) 100726].

Corrigendum to "Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor" [Biochem. Biophys. Rep. 21 (2020) 100726].

Journal: Biochemistry and biophysics reports

Published: December 31, 2020

A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys.

A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys.

Journal: Pharmacology research & perspectives

Published: December 21, 2019

Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor.

Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor.

Journal: Biochemistry and biophysics reports

Published: September 26, 2019

Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response.

Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 01, 2018

Pharmacological characteristics and clinical study results of the oral proteasome inhibitor ixazomib (NINLARO® capsules; 2.3 mg, 3 mg, and 4 mg)

Pharmacological characteristics and clinical study results of the oral proteasome inhibitor ixazomib (NINLARO® capsules; 2.3 mg, 3 mg, and 4 mg)

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: April 10, 2018

Amelioration of sexual behavior and motor activity deficits in a castrated rodent model with a selective androgen receptor modulator SARM-2f.

Amelioration of sexual behavior and motor activity deficits in a castrated rodent model with a selective androgen receptor modulator SARM-2f.

Journal: PloS one

Published: September 27, 2017

Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models.

Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models.

Journal: Oncology letters

Published: April 06, 2017

CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells.

CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells.

Journal: Oncotarget

Published: March 26, 2017

Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors.

Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors.

Journal: EBioMedicine

Published: March 06, 2017

Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate.

Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate.

Journal: Bioorganic & medicinal chemistry

Published: February 20, 2017

Showing 1-12 of 27

Last Updated: 09/26/2026